Please login to the form below

Not currently logged in
Email:
Password:

KRAS mutation

This page shows the latest KRAS mutation news and features for those working in and with pharma, biotech and healthcare.

Pfizer signs $507m cancer deal with Effector Therapeutics

Pfizer signs $507m cancer deal with Effector Therapeutics

This includes patients with any KRAS mutation, amplifications or fusions in HER2, ERBB3, FGFR1 or FGFR2 receptor tyrosine kinases.

Latest news

  • Merck strengthens KRAS stake with Taiho and Astex partnership Merck strengthens KRAS stake with Taiho and Astex partnership

    Another company looking to crack the KRAS mutation is Amgen, which recently announced some positive data for its pathfinder KRAS inhibitor AMG 510 in KRAS G12C-positive NSCLC. ... Other competitors in the KRAS inhibitor race include Mirati, Boehringer

  • Amgen reveals more data on KRAS drug Amgen reveals more data on KRAS drug

    It is estimated that around 14% of NSCLC adenocarcinoma patients and roughly 5% of colorectal cancer patients have the KRAS G12C mutation. ... Amgen is leading the field among companies developing inhibitors of KRAS, an oncogene that is implicated in

  • Boehringer bolsters KRAS push with $720m Lupin deal Boehringer bolsters KRAS push with $720m Lupin deal

    Once considered all-but ‘undruggable’, there are signs of progress in the KRAS field, with Amgen reporting encouraging anti-tumour activity with its  AMG 510 candidate – which targets a KRAS mutation ... the hope of providing “more effective and

  • Boehringer Ingelheim forms ‘virtual research’ alliance with MD Anderson Boehringer Ingelheim forms ‘virtual research’ alliance with MD Anderson

    Mutations in the KRAS pathway have been recognised for decades as a key part of oncology research. ... In June this year, Amgen reported safety, tolerability and preliminary anti-tumour activity in a phase 1 trial of a candidate which targets a KRAS

  • Has Amgen cracked KRAS? First clinical data says maybe Has Amgen cracked KRAS? First clinical data says maybe

    It is estimated that around 14% of NSCLC adenocarcinoma patients and roughly 5% of colorectal cancer patients have the KRAS G12C mutation. ... The KRAS G12C mutation has emerged as a clear front-runner among the various targets for pharmacological

More from news
Approximately 1 fully matching, plus 9 partially matching documents found.

Latest Intelligence

  • Interview: AstraZeneca's Susan Galbraith Interview: AstraZeneca's Susan Galbraith

    This includes people with NSCLC who have a mutated KRAS gene - an area where no specific treatment option exists. ... With selumetinib you've now got that plus another 20-25 per cent of NSCLC cases - people with the KRAS mutation.”.

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
An agency called Owen

We’re a Healthcare Communications Agency specialising in Multi-channel Marketing to make you Digitally Fitter, Stronger & Faster....

Latest intelligence

The ALS patient journey
Nick Goldup is the Director of Care Improvement at the Motor Neuron Disease Association (MNDA). Here, he offers his insights into the journey for patients with ALS and explores the...
Equipping your medical affairs teams with solutions to navigate the healthcare landscape
Dr Tyler Ray, OPEN Health Medical Communications...
Protein degraders
Can protein degraders unlock ‘undruggable’ drug targets?
Exploring a new and exciting area of small-molecule drug discovery...

Infographics